The percentage of Americans taking GLP-1 drugs such as Ozempic or Zepbound to lose weight has nearly quadrupled since 2024, according to a new survey by Gallup
Skov J, Dejgaard A, Frkir J, Holst JJ, Jonassen T, Rittig S, Christiansen JS
This peptides ability to restore neurotransmitter balance highlights its promise as a novel therapeutic agent for sleep disorders
In the Liraglutide Effects in Atrial Fibrillation (LEAF) Study, researchers at the University of Miami Miller School of Medicine, led by Jeffrey Goldberger, M.D., cardiac electrophysiologist and professor of cardiovascular medicine at the Miller School, found that adding the GLP1 receptor agonist liraglutide to a structured riskfactor modification program significantly improved freedom from AFib or atrial flutter one year after catheter ablation in overweight and obese patients